American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 474-484 , March 2010

Screening for CKD and Cardiovascular Disease Risk Factors Using Mobile Clinics in Jalisco, Mexico

  • Jose Alfonso Gutierrez-Padilla, MD, MPH

      Affiliations

    • Fundacion Hospitales Civiles de Guadalajara AC, Guadalajara, Jalisco, Mexico
    • ,
  • Martha Mendoza-Garcia, MD

      Affiliations

    • Fundacion Hospitales Civiles de Guadalajara AC, Guadalajara, Jalisco, Mexico
    • ,
  • Salvador Plascencia-Perez, MD

      Affiliations

    • Fundacion Hospitales Civiles de Guadalajara AC, Guadalajara, Jalisco, Mexico
    • ,
  • Karina Renoirte-Lopez, MD

      Affiliations

    • Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico
    • ,
  • Guillermo Garcia-Garcia, MD

      Affiliations

    • Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico
    • Corresponding Author InformationAddress correspondence to Guillermo Garcia-Garcia, MD, Hospital Civil de Guadalajara “Fray Antonio Alcalde,” Hospital 278, Apdo Postal 2-70, 44280 Guadalajara, Jalisco, Mexico
    • ,
  • Anita Lloyd, MSc

      Affiliations

    • University of Alberta, Edmonton, Canada
    • ,
  • Marcello Tonelli, MD, SM

      Affiliations

    • University of Alberta, Edmonton, Canada

Received 1 May 2009 ,Accepted 30 July 2009.

References 

  1. Frenk J, Gonzalez Block MA, Knaul F, Solis F, Villagomez FA. La Seguridad Social en Salud: Perspectivas para la Reforma. In: La Seguridad Social en Mexico. Mexico City: Fondo de Cultura Economica; 1999;p. 35–102
  2. Secretaria de Salud. Salud: Mexico 2005: Información Para la Rendicion de Cuentas. 2005;Mexico City, Mexico
  3. Olaiz G, Rojas R, Barquera S. Encuesta Nacional de Salud 2000 (Tomo 2). Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública; 2003;
  4. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública; 2006;
  5. US Renal Data System. Atlas of End-Stage Renal Disease in the United States International Comparisons (USRDS 2008 Annual Data Report). Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;
  6. Sistema Nacional de Información en Salud-SINAIS. Estadisticas por tema. http://www.sinais.salud.gob.mxAccessed November 30, 2008
  7. Garcia-Garcia G, Monteon-Ramos JF, Garcia-Bejarano H, et al. Renal replacement therapy among disadvantaged populations in Mexico: a report from the Jalisco Dialysis and Transplant Registry (REDTJAL). Kidney Int Suppl. 2005;97(68):S58–S61
  8. Garcia-Garcia G, Briseno-Renteria G, Luquin-Arellano VH, Gao Z, Gill J, Tonelli M. Survival among patients with kidney failure in Jalisco, Mexico. J Am Soc Nephrol. 2007;18(6):1922–1927
  9. Levey AS, Schoolwerth AC, Burrows NR, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53(3):522–535
  10. Koshy SM, Garcia-Garcia G, Sandoval Pamplona J, et al. Screening for kidney disease in children on World Kidney Day in Jalisco, Mexico. Pediatr Nephrol. 2009;24:1219–1225
  11. Consejo Estatal de Poblacion, Jalisco. Estadisticas. http://www.coepo.jalisco.gob.mxAccessed November 30, 2008
  12. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2571
  13. National Cholesterol Education Program (NCEP) Expert Panel. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health; 2002;
  14. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Am J Kidney Dis. 2002;39(2 suppl 1):S76–S110
  15. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Technical Report Series No. 894 Geneva, Switzerland: WHO; 2000;
  16. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371(9616):923–931
  17. Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333(7577):1047–1050
  18. Manson JE, Skerrett PJ, Greenland P, VanItallie TB. The escalating pandemics of obesity and sedentary lifestyle (A call to action for clinicians). Arch Intern Med. 2004;164(3):249–258
  19. Hallan S, de Mutsert R, Carlsen S, Dekker F, Aasarod K, Holmen J. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable?. Am J Kidney Dis. 2006;47(3):396–405
  20. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047
  21. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab Kidney Study. J Am Soc Nephrol. 2003;14(7 suppl 2):S131–S138
  22. Li PK, Kwan BC, Leung CB, et al. Prevalence of silent kidney disease in Hong Kong: the Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. Kidney Int Suppl. 2005;94:S36–S40
  23. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am Soc Nephrol. 2002;13(7):1907–1917
  24. Mani MK. Experience with prevention programs in the Asian Pacific Region. Kidney Int Suppl. 2005;67:S75–S78
  25. Dirks JH, de ZD, Agarwal SK, et al. Prevention of chronic kidney and vascular disease: toward global health equity—the Bellagio 2004 Declaration. Kidney Int Suppl. 2005;98:S1–S6
  26. Dirks JH, Robinson SW, Alderman M, et al. Meeting report on the Bellagio Conference “Prevention of Vascular Diseases in the Emerging World: An Approach to Global Health Equity.”. Kidney Int. 2006;70(8):1397–1402
  27. Mani MK. Nephrologists sans frontieres: preventing chronic kidney disease on a shoestring. Kidney Int. 2006;70(5):821–823
  28. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330(13):877–884
  29. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986
  30. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease (A meta-analysis of patient-level data). Ann Intern Med. 2001;135(2):73–87
  31. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–1462
  32. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41(3):565–570
  33. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14(6):1605–1613

 Originally published online as doi:10.1053/j.ajkd.2009.07.023 on October 22, 2009.

 No paper or electronic reprints will be available.

PII: S0272-6386(09)01083-X

doi: 10.1053/j.ajkd.2009.07.023

American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 474-484 , March 2010

Article Tools

* Image Usage & Resolution